201417-12-1
201417-12-1
Chemical Structure
L-DOPA-13C6
Synonym(s): Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6
- CAS. Nr.: 201417-12-1
- Formula:C313C6H11NO4
- Molecular Weight:203.14
IUPAC Name: (S)-2-amino-3-(3,4-dihydroxyphenyl-1,2,3,4,5,6-13C6)propanoic acid
InChIKey: WTDRDQBEARUVNC-XXRLIUPJSA-N
SMILES: OC([C@@H](N)C[13C]1=[13CH][13C](O)=[13C]([13CH]=[13CH]1)O)=O
Biological Activity: L-DOPA-13C6 is the 13C-labled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
L-DOPA-13C6 | 99.11% | L-DOPA-13C6 is the 13C-labled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-DOPA (Standard) | 99.86% | L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-DOPA-2,5,6-d3 | 98.80% | L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-DOPA-13C | 99.77% | L-DOPA-13C is the 13C labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-DOPA-d6 | 99.48% | L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SD-1077 | SD-1077 is a selectively deuterated precursor of dopamine (DA). SD-1077 can be used for the study of Parkinson's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-DOPA | 99.98% | L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38(12):2405-10. [Content Brief]
- [3]. Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 200814(4):273-80. Epub 2007 Nov 7. [Content Brief]
- [4]. Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 310:237. [Content Brief]
